Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma

• ClinicalTrials.gov Identifier: NCT01258608
• Recruitment Status: Completed
• First Posted: December 13, 2010
• Results First Posted: December 19, 2018
• Last Update Posted: December 19, 2018
• Sponsor: Human Genome Sciences Inc., a GSK Company
• Collaborator: GlaxoSmithKline
• Information provided by (Responsible Party): GlaxoSmithKline ( Human Genome Sciences Inc., a GSK Company )

Study Description

Brief Summary:

Mapatumumab is a fully human, agonist monoclonal antibody that activates the cell death pathway in tumor cells by specifically binding to TRAIL-R1 with high affinity. Sorafenib, a multikinase inhibitor, is the standard of care for treatment of patients with advanced hepatocellular carcinoma (HCC). The mechanisms of sorafenib and mapatumumab action suggest that these agents could interact synergistically. This is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of mapatumumab in combination with sorafenib in subjects with advanced hepatocellular carcinoma.

Condition or disease	Intervention/treatment	Phase
Carcinoma, Hepatocellular	Drug: Mapatumumab; Drug: Placebo; Drug: Sorafenib	Phase 1; Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 101 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double (Participant, Investigator)
• Primary Purpose: Treatment
• Official Title: A Randomized, Multi-Center, Blinded, Placebo-Controlled Study Of Mapatumumab ([HGS1012], A Fully Monoclonal Antibody To TRAIL-R1) In Combination With Sorafenib As A First-Line Therapy In Subjects With Advanced Hepatocellular Carcinoma
• Actual Study Start Date: February 8, 2011
• Actual Primary Completion Date: May 31, 2013
• Actual Study Completion Date: November 29, 2017

Arms and Interventions

Arm	Intervention/treatment
Experimental: Sorafenib plus mapatumumab; Mapatumumab 30 milligrams (mg)/kilogram (kg) intravenously on Day 1 of each cycle (i.e. every 21 days) plus sorafenib 400 mg orally twice daily continuously in each cycle until radiologic disease progression or unacceptable toxicity	Drug: Mapatumumab; Mapatumumab will be supplied as a lyophilized formulation in 10 mL vials containing 100 mg mapatumumab for intravenous infusion at the dose of 30 mg/kg.; Drug: Sorafenib; Sorafenib will be supplied as tablets, each containing 274 mg sorafenib tosylate, equivalent to 200 mg of sorafenib, to be administered 400 mg (2 x 200 mg tablets) orally twice daily.
Placebo Comparator: Sorafenib plus Placebo; Placebo intravenously on Day 1 of each cycle (i.e. every 21 days) plus sorafenib 400 mg orally twice daily continuously in each cycle until radiologic disease progression or unacceptable toxicity	Drug: Placebo; Normal saline solution for intravenous infusion will be administered as placebo for mapatumumab; Drug: Sorafenib; Sorafenib will be supplied as tablets, each containing 274 mg sorafenib tosylate, equivalent to 200 mg of sorafenib, to be administered 400 mg (2 x 200 mg tablets) orally twice daily.

Outcome Measures

Primary Outcome Measures :

1. Time to Progression-Blinded Independent Central Review (BICR) Assessment [ Time Frame: Randomization to maximum of 24.1 months ]
   Time to progression is defined as the time from randomization to radiologic disease progression based on blinded independent review (BICR) of imaging scans using modified Response Evaluation Criteria in Solid Tumors assessment (mRECIST) for hepatocellular carcinoma. The primary analysis was performed using Kaplan Meier methods. The median time to progression is reported with one-sided 90% confidence interval. Analysis was performed on the modified Intent to Treat (mITT) Population which comprised of all randomized participants who received at least part of 1 dose of study agent (mapatumumab/placebo and/or sorafenib) with participants analyzed according to the groups to which they were randomized. NA indicates upper limit was not measurable as one-sided confidence interval is presented.

Secondary Outcome Measures :

1. Time to Progression-Investigator Assessment [ Time Frame: Randomization to maximum of 52.9 months ]
   Time to progression is defined as the time from randomization to radiologic disease progression. The primary analysis was performed using Kaplan Meier methods based on application of mRECIST for hepatocellular carcinoma to investigator assessments. The median time to progression is reported with one-sided 90% confidence interval. NA indicates upper limit was not measurable as one-sided confidence interval is presented.
2. Median Overall Survival [ Time Frame: Randomization to maximum of 52.9 months ]
   Overall survival is defined as time from randomization to death from any cause. The analysis was performed using Kaplan Meier methods. The median overall survival is reported with one-sided 90% confidence interval. NA indicates upper limit was not measurable as one-sided confidence interval is presented.
3. Progression Free Survival-BICR Assessment [ Time Frame: Randomization to maximum of 24.1 months ]
   Progression free survival is defined as time from randomization to radiologic disease progression or death from any cause. The analysis was performed using Kaplan Meier methods using BICR assessment of imaging scans. The median progression free survival is reported with one-sided 90% confidence interval. NA indicates upper limit was not measurable as one-sided confidence interval is presented.
4. Progression Free Survival-Investigator Assessment [ Time Frame: Randomization to maximum of 52.9 months ]
   Progression free survival is defined as time from randomization to radiologic disease progression or death from any cause. The analysis was performed using Kaplan Meier methods based on application of mRECIST for hepatocellular carcinoma to investigator assessments. The median progression free survival is reported with one-sided 90% confidence interval. NA indicates upper limit was not measurable as one-sided confidence interval is presented.
5. Percentage of Participants With Objective Response-BICR Assessment [ Time Frame: Randomization to maximum of 24.1 months ]
   Objective response rate is defined as the percentage of participants with complete response+partial response according to mRECIST criteria for hepatocellular carcinoma using BICR assessment of imaging scans. The percentage of participants with objective response is reported along with 95% confidence interval.
6. Percentage of Participants With Objective Response-Investigator Assessment [ Time Frame: Randomization to maximum of 52.9 months ]
   Objective response rate is defined as the percentage of participants with complete response+partial response according to mRECIST criteria for hepatocellular carcinoma to investigator assessments. The percentage of participants with objective response is reported along with 95% confidence interval.
7. Percentage of Participants With Disease Control-BICR Assessment [ Time Frame: Randomization to maximum of 24.1 months ]
   Disease control rate is the percentage of participants with complete response+partial response+stable disease according to mRECIST criteria for hepatocellular carcinoma. The end point was based on BICR assessment of imaging scans. The percentage of participants with disease control is presented along with 95% confidence interval.
8. Percentage of Participants With Disease Control-Investigator Assessment [ Time Frame: Randomization to maximum of 52.9 months ]
   Disease control rate is the percentage of participants with complete response+partial response+stable disease according to mRECIST criteria for hepatocellular carcinoma to investigator assessments. The percentage of participants with disease control is presented along with 95% confidence interval.
9. Time to Response-BICR Assessment [ Time Frame: Randomization to maximum of 24.1 months ]
   Time to response is defined as time from randomization to first partial response or complete response in responders only. Complete Response (CR): Disappearance of intratumoral arterial enhancement in all target lesions. Partial Response (PR): At least a 30% decrease in the sum of diameters of viable (enhancement in the arterial phase) target lesions, taking as reference the baseline sum of the diameters of target lesions
10. Duration of Response-BICR Assessment [ Time Frame: Randomization to maximum of 24.1 months ]
    Duration of response is defined as time from first PR or CR to radiologic disease progression; in responders only. CR: Disappearance of intratumoral arterial enhancement in all target lesions. PR: At least a 30% decrease in the sum of diameters of viable (enhancement in the arterial phase) target lesions, taking as reference the Baseline sum of the diameters of target lesions. Progressive disease (PD): An increase of at least 20% in the sum of the diameters of viable (enhancing) target lesions, taking as reference the smallest sum of the diameters of viable (enhancing) target lesions recorded since treatment started.
11. Number of Participants With Treatment-emergent Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: Start of study treatment to maximum of 52.9 months ]
    An AE is any unfavorable or unintended sign, symptom, or disease that is temporally associated with the use of a study agent but is not necessarily caused by the study agent. An SAE is an adverse event resulting in any of the following outcomes: death, life-threatening, inpatient hospitalization, prolongation of an existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect or other medically important events that may jeopardize the participant or may require intervention to prevent one of the other outcomes mentioned before. A treatment-emergent AE is an AE that emerged during treatment, having been absent pre-treatment, or worsened relative to the pre-treatment state. As-Treated Population comprised of participants who received at least part of 1 dose of study agent analyzed according to the treatment that they actually received.
12. Number of Participants With Severe AEs [ Time Frame: Start of study treatment to maximum of 52.9 months ]
    An AE is any unfavorable or unintended sign, symptom, or disease that is temporally associated with the use of a study agent but is not necessarily caused by the study agent. Severity of AEs were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.0. Grade 1 represents mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 represents moderate; minimal, local or non-invasive intervention indicated. Grade 3 represents severe or medically significant but not immediately life -threatening; hospitalization or prolongation of hospitalization indicated; disabling. Grade 4 represents life -threatening consequences; urgent intervention indicated. Grade 5 represents death related to AE. Severe AE is defined as AEs classified by investigator as severe (causing inability to carry out usual activities), life threatening or fatal using NCI-CTCAE Version 4.0 grading.
13. Number of Participants With Worst Toxicity Grade-chemistry Parameters [ Time Frame: Enrolment to maximum of 52.9 months ]
    Blood samples were collected for the evaluation of following chemistry parameters: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), amylase, bilirubin, gamma glutamyl transferase (GGT), calcium, potassium, magnesium, albumin, sodium and creatinine. Laboratory toxicities were graded based on the NCI-CTCAE version 4.0. Grade 1 represents mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 represents moderate; minimal, local or non-invasive intervention indicated. Grade 3 represents severe or medically significant but not immediately life -threatening; hospitalization or prolongation of hospitalization indicated; disabling. Grade 4 represents life -threatening consequences; urgent intervention indicated. Number of participants with worst toxicity grades for any abnormalities observed in any chemistry parameters during the study is presented.
14. Number of Participants With Worst Toxicity Grade-hematology Parameters [ Time Frame: Enrolment to maximum of 52.9 months ]
    Blood samples were collected for assessment of the following hematology parameters: activated partial thromboplastin time (APTT), hemoglobin, international normalized ratio (INR), lymphocytes, neutrophils, platelets and white blood cells (WBC). Laboratory toxicities were graded based on the NCI-CTCAE version 4.0. Grade 1 represents mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 represents moderate; minimal, local or non-invasive intervention indicated. Grade 3 represents severe or medically significant but not immediately life -threatening; hospitalization or prolongation of hospitalization indicated; disabling. Grade 4 represents life -threatening consequences; urgent intervention indicated. Number of participants with worst toxicity grades for any abnormalities observed in any hematology parameters during the study is presented.
15. Number of Participants With Anti-mapatumumab Antibodies [ Time Frame: Randomization to maximum of 24.1 months ]
    Blood samples were collected for the assessment of serum antibodies. The presence of anti-mapatumumab antibodies was assessed using a validated electrochemiluminescent immunoassay. The assay incorporated a tiered testing approach which used screening and confirmation steps. The anti-drug antibody (ADA) confirmed positive participants were separated into transient or persistent antibody positives. Persistent positive refers to positive immunogenic response at 2 or more assessments or at the final assessment. Transient positive refers to positive immunogenic response at only 1 assessment and negative at the final assessment.
16. Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) [ Time Frame: Baseline and Day 1 of Cycles 2 to 75 (each cycle of 21 days) ]
    SBP and DBP were obtained on Day 1 of each cycle. Baseline is the last assessment prior to first dose. Change from Baseline is the value at indicated time point minus the value at Baseline. NA indicates standard deviation could not be calculated as only one participant was analyzed at the specified time point.
17. Change From Baseline in Heart Rate [ Time Frame: Baseline and Day 1 of Cycles 2 to 75 (each cycle of 21 days) ]
    Heart rate was obtained on Day 1 of each cycle. Baseline is the last assessment prior to first dose. Change from Baseline is the value at indicated time point minus the value at Baseline. NA indicates standard deviation could not be calculated as only one participant was analyzed at the specified time point.
18. Change From Baseline in Temperature [ Time Frame: Baseline and Day 1 of Cycles 2 to 75 (each cycle of 21 days) ]
    Temperature was obtained on Day 1 of each cycle. Baseline is the last assessment prior to first dose. Change from Baseline is the value at indicated time point minus the value at Baseline. NA indicates standard deviation could not be calculated as only one participant was analyzed at the specified time point.
19. Change From Baseline in Respiratory Rate [ Time Frame: Baseline and Day 1 of Cycles 2 to 75 (each cycle of 21 days) ]
    Respiratory rate was obtained on Day 1 of each cycle. Baseline is the last assessment prior to first dose.Change from Baseline is the value at indicated time point minus the value at Baseline. NA indicates standard deviation could not be calculated as only one participant was analyzed at the specified time point.
20. Change From Baseline in Weight [ Time Frame: Baseline and Day 1 of Cycles 2 to 75 (each cycle of 21 days) ]
    Weight was obtained on Day 1 of each cycle. Baseline is the last assessment prior to first dose. Change from Baseline is the value at indicated time point minus the value at Baseline. NA indicates standard deviation could not be calculated as only one participant was analyzed at the specified time point.
21. Serum Concentration of Mapatumumab [ Time Frame: Day1 pre-dose(Cycle 1,2,4,5,6,8,9,10,12,14,16,17,18,20,22,24,26,28,30,32,34);end of infusion (Cycle 1);Day8 pre-dose(Cycle 1);Day15 pre-dose (Cycle 1,2);Day21(Cycle 2,4,6,8,9,12,14,16,18,20,22,24,26,28,30,32,34);Cycle 99(end of treatment) (21-day cycles) ]
    Blood samples were collected for determination of serum mapatumumab concentration at the indicated time points. NA indicates standard deviation could not be calculated as only one participant was analyzed at the specified time points.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Child-Pugh Class A.
• Barcelona Clinic Liver Cancer (BCLC) advanced stage (C) hepatocellular carcinoma, or BCLC intermediate stage (B) hepatocellular carcinoma if treatment with transarterial chemoembolization is not considered appropriate
• Measurable disease demonstrating intratumoral arterial enhancement by contrast enhanced computerized tomography (CT), with use of multislice scanners, or contrast enhanced dynamic magnetic resonance imaging (MRI), with at least 1 tumor lesion that meets the following criteria: located in the liver; can be accurately measured in at least 1 dimension; well delineated area of viable, hypervascular (contrast enhancement in the arterial phase) tumor that is >2 centimeter (cm) in the axial plane; suitable for repeat measurement; OR not previously treated with locoregional or systemic treatment unless the lesion shows a well-delineated area of viable (contrast enhancement in the arterial phase) tumor that is >2 cm in the axial plane. (If the lesion is poorly demarcated or exhibits atypical enhancement as a result of the previous intervention, then it cannot be selected as a target lesion)
• Radiologic eligibility (measurable disease) must be must be confirmed by the BICR prior to randomization.
• Adequate bone marrow, renal and liver function as defined in the protocol.
• Performance status of 0, 1 or 2 on the Eastern Cooperative Oncology Group (ECOG) Scale
• Age 18 years or older
• Have the ability to understand the requirements of the study, provide written informed consent (including consent for the use and disclosure of research-related health information), and comply with the study and follow-up procedures.

Exclusion Criteria:

• Any co-morbid condition that in the judgment of the investigator renders the subject at high risk of treatment complications or reduces the possibility of assessing clinical effect.
• Received prior investigational or non-investigational cytotoxic chemotherapy, hormonal therapy, biological therapy (including but not limited to monoclonal antibodies, small molecules or other immunotherapy) to treat hepatocellular carcinoma.
• History of organ allograft.
• Previously received mapatumumab or sorafenib.
• Underwent resection, radiofrequency ablation, radiation or chemoembolization within 4 weeks before enrollment or not recovered from such treatments.
• Need for concomitant anticancer therapy (surgery, radiation therapy, chemotherapy, immunotherapy, radiofrequency ablation) or other investigational agents during the study treatment period.
• Major surgery (i.e., the opening of a major body cavity, requiring the use of general anesthesia) within 4 weeks before enrollment; minor surgery (except for insertion of vascular access device) within 2 weeks before enrollment; or not yet recovered from the effects of the surgery.
• Systemic steroids within 1 week before enrollment except steroids used as part of an antiemetic regimen or maintenance-dose steroids for non-cancerous disease.
• Hepatic encephalopathy, per the investigator's evaluation.
• History of clinically significant gastrointestinal bleeding requiring procedural intervention (e.g., variceal banding, transjugular intrahepatic portosystemic shunt procedure, arterial embolization, topical coagulation therapy) within 4 weeks before enrollment.
• Gastrointestinal disease resulting in an inability to take oral medication or a requirement for intravenous hyperalimentation.
• History of any infection requiring hospitalization or intravenous antibiotics within 2 weeks before enrollment.
• Known brain or spinal cord metastases unless adequately treated (surgery or radiotherapy) with no evidence of progression and neurologically stable off anticonvulsants and steroids.
• Known human immunodeficiency virus infection.
• Unstable angina, myocardial infarction, cerebrovascular accident, >= Class II congestive heart failure according to the New York Heart Association Classification for Congestive Heart Failure within 6 months before enrollment.
• Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin.
• Uncontrolled hypertension (systolic blood pressure >150 millimeters of mercury [mmHg] or diastolic pressure >90 mmHg despite optimal medical management).
• Using and unable to discontinue use of concomitant strong CYP3A4 inducers (e.g., including but not limited to St. John's Wort, dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, phenobarbital)
• Pregnant female or nursing mother. All females with an intact uterus (unless amenorrheic for the 24 months before enrollment) must have a negative serum pregnancy test at screening. All non-sterile or non-postmenopausal females must practice a medically accepted method of contraception over the course of the study and for 60 days after the last dose of study agent.
• Males who do not agree to use effective contraception during the study and for a period of 60 days following the final dose of study agent.
• Subject is currently enrolled in or has not yet completed at least 30 days since ending other investigational device or drug study(s) or subject is receiving other investigational agents.
• Acute or chronic severe renal insufficiency (glomoerular filtration rate <30 milliliters [mL]/minute/1.73 square meters) or acute renal insufficiency of any severity due to the hepato-renal syndrome.
• Hepatitis B virus deoxyribonucleic acid (DNA) levels >2,000 international units/mL.

Contacts and Locations

Locations

United States, Colorado

GSK Investigational Site

Aurora, Colorado, United States, 80045

United States, Louisiana

GSK Investigational Site

Shreveport, Louisiana, United States, 71103

United States, Minnesota

GSK Investigational Site

Rochester, Minnesota, United States, 55905

United States, Mississippi

GSK Investigational Site

Tupelo, Mississippi, United States, 38801

United States, New Jersey

GSK Investigational Site

Newark, New Jersey, United States, 07103

United States, Pennsylvania

GSK Investigational Site

Hershey, Pennsylvania, United States, 17033-0850

GSK Investigational Site

Hershey, Pennsylvania, United States, 17033-

GSK Investigational Site

Philadelphia, Pennsylvania, United States, 19104

GSK Investigational Site

Pittsburgh, Pennsylvania, United States, 15232

Germany

GSK Investigational Site

Muenchen, Bayern, Germany, 81377

GSK Investigational Site

Frankfurt, Hessen, Germany, 60590

GSK Investigational Site

Hannover, Niedersachsen, Germany, 30625

GSK Investigational Site

Hamburg, Germany, 20246

Poland

GSK Investigational Site

Gdansk, Poland, 80-952

GSK Investigational Site

Olsztyn, Poland, 10-228

GSK Investigational Site

Poznan, Poland, 61-878

GSK Investigational Site

Szczecin, Poland, 71-730

GSK Investigational Site

Warszawa, Poland, 02-507

GSK Investigational Site

Warszawa, Poland, 04-125

Puerto Rico

GSK Investigational Site

San Juan, Puerto Rico, 00927

Romania

GSK Investigational Site

Bucuresti, Romania, 022328

GSK Investigational Site

Cluj-Napoca, Romania, 400015

GSK Investigational Site

Craiova, Romania, 200385

GSK Investigational Site

Iasi, Romania, 700483

Russian Federation

GSK Investigational Site

Ekaterinburg, Russian Federation, 620036

GSK Investigational Site

Kazan, Russian Federation, 420029

GSK Investigational Site

Krasnoyarsk, Russian Federation, 660133

GSK Investigational Site

Moscow, Russian Federation, 115478

GSK Investigational Site

Moscow, Russian Federation, 125284

GSK Investigational Site

Moscow, Russian Federation, 195067

GSK Investigational Site

Pyatigorsk, Russian Federation, 357502

GSK Investigational Site

St-Petersburg, Russian Federation, 194017

GSK Investigational Site

St. Petersburg, Russian Federation, 198255

GSK Investigational Site

Tomsk, Russian Federation, 634050

GSK Investigational Site

Yaroslavl, Russian Federation, 150054

Ukraine

GSK Investigational Site

Dnipropetrovsk, Ukraine, 49044

GSK Investigational Site

Donetsk, Ukraine, 83092

GSK Investigational Site

Kharkiv, Ukraine, 61070

GSK Investigational Site

Kyiv, Ukraine, 03022

GSK Investigational Site

Kyiv, Ukraine, 03039

GSK Investigational Site

Lviv, Ukraine, 79031

GSK Investigational Site

Uzhhorod, Ukraine, 88014

GSK Investigational Site

Zaporizhia, Ukraine, 69032

Sponsors and Collaborators

Human Genome Sciences Inc., a GSK Company

GlaxoSmithKline

Investigators

• Study Director: GSK Clinical Trials; GlaxoSmithKline
• Study Director: GSK Clinical Trials; GlaxoSmithKline (for GlaxoSmithKline; Human Genome Sciences Inc., a GSK Company; Sirtris, a GSK Company; Stiefel, a GSK Company; ViiV Healthcare)

  Study Documents (Full-Text)

Documents provided by GlaxoSmithKline ( Human Genome Sciences Inc., a GSK Company ):

Study Protocol  [PDF] July 15, 2015

Statistical Analysis Plan  [PDF] November 10, 2011

More Information

Additional Information:

Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research. 

Study Data/Documents: Study Protocol 

Identifier: 200149
For additional information about this study please refer to the GSK Clinical Study Register

Informed Consent Form 

Identifier: 200149
For additional information about this study please refer to the GSK Clinical Study Register

Statistical Analysis Plan 

Identifier: 200149
For additional information about this study please refer to the GSK Clinical Study Register

Clinical Study Report 

Identifier: 200149
For additional information about this study please refer to the GSK Clinical Study Register

Individual Participant Data Set 

Identifier: 200149
For additional information about this study please refer to the GSK Clinical Study Register

Dataset Specification 

Identifier: 200149
For additional information about this study please refer to the GSK Clinical Study Register

Publications:

Ciuleanu T, Bazin I, Lungulescu D, Miron L, Bondarenko I, Deptala A, Rodriguez-Torres M, Giantonio B, Fox NL, Wissel P, Egger J, Ding M, Kalyani RN, Humphreys R, Gribbin M, Sun W. A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma. Ann Oncol. 2016 Apr;27(4):680-7. doi: 10.1093/annonc/mdw004. Epub 2016 Jan 22.

• Responsible Party: Human Genome Sciences Inc., a GSK Company
• ClinicalTrials.gov Identifier: NCT01258608
• Other Study ID Numbers: 200149; HGS1012-C1103 ( Other Identifier: Human Genome Sciences Inc. )
• First Posted: December 13, 2010
• Results First Posted: December 19, 2018
• Last Update Posted: December 19, 2018
• Last Verified: November 2018

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Yes
• Plan Description: Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

Keywords provided by GlaxoSmithKline ( Human Genome Sciences Inc., a GSK Company ):

advanced hepatocellular carcinoma; Mapatumumab; HGS1012; sorafenib

Additional relevant MeSH terms:

Carcinoma; Carcinoma, Hepatocellular; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Adenocarcinoma; Liver Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Digestive System Diseases; Liver Diseases; Sorafenib; Mapatumumab; Antineoplastic Agents; Protein Kinase Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action